Adjusting for screening history in epidemiologic studies of cancer: Why, when, and how to do it

American Journal of Epidemiology

Volumn 157, Issue 11, 2003, Pages 957-961

  Weiss, Noel S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Confounding factors (epidemiology); Effect modifiers (epidemiology); Neoplasms

Indexed keywords

ESTROGEN; HORMONE; NONSTEROID ANTIINFLAMMATORY AGENT;

CANCER;

ACCURACY; ANAMNESIS; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER SCREENING; CLINICAL FEATURE; COLON CARCINOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EARLY DIAGNOSIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; EPIDEMIOLOGICAL DATA; ESTROGEN THERAPY; HIGH RISK POPULATION; HUMAN; MALIGNANT TRANSFORMATION; MAMMOGRAPHY; PRECANCER; REVIEW; RISK ASSESSMENT; SCREENING TEST; TUMOR DIFFERENTIATION; UTERUS BLEEDING;

EID: 0037849858     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwg062     Document Type: Review

References (14)

1. Gustafsson L, Ponten J, Zack M, et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997;8:755-63.
2. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7.
3. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papilloma-virus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000;92:464-74.
4. Schiff M, Miller J, Masuk M, et al. Contraceptive and reproductive risk factors for cervical intraepithelial neoplasia in American Indian women. Int J Epidemiol 2000;29:983-98.
5. Szekely DR, Weiss NS, Schweid Al. The incidence of endometrial cancer in King County, Washington: a standardized histologic review. J Natl Cancer Inst 1978;60:985-9.
6. Morrison AS. Screening in chronic disease. 2nd ed. New York, NY: Oxford University Press, 1992.
7. Fontana RS, Sanderson DR, Woolner LB, et al. Lung cancer screening: the Mayo program. J Occup Med 1986;28:746-50.
8. Marcus PM, Bergstrath EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 2000;92:1308-16.
9. MacMahon B, Trichopoulos D. Epidemiology: principles and methods. 2nd ed. Boston, MA: Little Brown, 1996.
10. Walter SD, Day NE. Estimation of the duration of a preclinical disease state using screening data. Am J Epidemiol 1983;118: 865-86.
11. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. Br Med J (Clin Res Ed) 1986;293:659-64.
12. Joffe MM, Byrne C, Colditz GA. Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias. Epidemiology 2001;12:429-38.
13. Laya MB, Larson EB, Taplin SH, et al. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 1996;88:643-9.
14. Horwitz RI, Feinstein AR. Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 1978;299:1089-94.